Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Christopher T. Fair B.B.A. | CEO & Director | 724.6k | -- | 1970 |
| Mr. Daniel Geiger | Chief Financial Officer | -- | -- | 1971 |
| Mr. Sjoerd Musters | COO & GM of BV | -- | -- | 1980 |
| Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D. | President of Innovation and Strategy & Executive Director | -- | -- | 1966 |
| Mr. G. Joseph Ross | Senior Vice President of Marketing & Business Development | -- | -- | 1968 |
| Ms. Nikki Coleman | Vice President of Global Human Resources | -- | -- | -- |
| Dr. Philippe Saudan Ph.D. | Chief Development Officer | -- | -- | 1967 |
| Mr. John Griffin | Chief Commercial Officer | -- | -- | -- |
| Dr. Katherine Sage D.O., FAAOS, M.S. | Senior Vice President of Medical & Clinical Affairs | -- | -- | -- |
| Dr. Virginia Jamieson | Consultant | -- | -- | 1953 |
Kuros Biosciences AG
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 122
Description
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Corporate Governance
Upcoming Events
March 11, 2025 at 6:00 AM UTC
Kuros Biosciences AG Earnings Date
Recent Events
October 8, 2020 at 12:00 AM UTC
Dividend Date